Walleye Capital
RXRX icon

Walleye Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Walleye Capital’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-30,882
Closed -$221K – 2684
2022
Q1 		$221K Buy
+30,882
New +$328K 0.01% 1459

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OMS
Obvious Management Services San Francisco, California $42.4M AUM 54.5% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Walleye Capital's RXRX Position: Q2 2022 in Review

Walleye Capital sold out of Recursion Pharmaceuticals (RXRX) in Q2 2022, closing a stake of 30,882 shares — an estimated $221K sold.

Walleye Capital first reported a position in RXRX in Q1 2022 and held it in 1 quarter. The position peaked at $221K in Q1 2022. 133 funds tracked by Wall St. Rank hold RXRX as of Q2 2022.

  • Walleye Capital reported no remaining Recursion Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Walleye Capital sold 30,882 Recursion Pharmaceuticals shares in Q2 2022, an estimated $221K.
  • Walleye Capital first reported a position in Recursion Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Walleye Capital's Recursion Pharmaceuticals position peaked at $221K in Q1 2022.
  • 133 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2022.

Based on Walleye Capital's 13F filing for Q2 2022, filed 8 Aug 2022.